Suzanne Conzen to Receptors, Glucocorticoid
This is a "connection" page, showing publications Suzanne Conzen has written about Receptors, Glucocorticoid.
Connection Strength
8.688
-
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration. Breast Cancer Res Treat. 2025 Feb; 209(3):563-572.
Score: 0.793
-
Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models. J Gynecol Oncol. 2025 Jan; 36(1):e4.
Score: 0.769
-
Glucocorticoid receptor-mediated oncogenic activity is dependent on breast cancer subtype. J Steroid Biochem Mol Biol. 2024 10; 243:106518.
Score: 0.763
-
Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association. Breast Cancer Res. 2019 07 24; 21(1):82.
Score: 0.548
-
Recent advances in understanding glucocorticoid receptor function in cancer. Clin Adv Hematol Oncol. 2017 May; 15(5):338-340.
Score: 0.469
-
GR and ER Coactivation Alters the Expression of Differentiation Genes and Associates with Improved ER+ Breast Cancer Outcome. Mol Cancer Res. 2016 08; 14(8):707-19.
Score: 0.438
-
Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer. Horm Cancer. 2016 Apr; 7(2):114-26.
Score: 0.431
-
Glucocorticoid receptor ChIP-sequencing of subcutaneous fat reveals modulation of inflammatory pathways. Obesity (Silver Spring). 2015 Nov; 23(11):2286-93.
Score: 0.420
-
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol. 2015 Sep; 138(3):656-62.
Score: 0.413
-
Gene expression of peripheral blood cells reveals pathways downstream of glucocorticoid receptor antagonism and nab-paclitaxel treatment. Pharmacogenet Genomics. 2014 Sep; 24(9):451-8.
Score: 0.390
-
Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6163-72.
Score: 0.364
-
The influence of glucocorticoid signaling on tumor progression. Brain Behav Immun. 2013 Mar; 30 Suppl:S26-31.
Score: 0.345
-
Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res. 2011 Oct 15; 71(20):6360-70.
Score: 0.316
-
Glucocorticoid receptor expression in breast cancer associates with older patient age. Breast Cancer Res Treat. 2009 Aug; 116(3):441-7.
Score: 0.256
-
Glucocorticoid receptor activation signals through forkhead transcription factor 3a in breast cancer cells. Mol Endocrinol. 2006 Oct; 20(10):2304-14.
Score: 0.219
-
Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem. 2005 Feb 11; 280(6):4117-24.
Score: 0.199
-
Glucocorticoid Receptor (GR) Activation Is Associated with Increased cAMP/PKA Signaling in Castration-Resistant Prostate Cancer. Mol Cancer Ther. 2024 Apr 02; 23(4):552-563.
Score: 0.189
-
Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem. 2001 May 18; 276(20):16649-54.
Score: 0.153
-
The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res. 2000 Feb 15; 60(4):867-72.
Score: 0.142
-
Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer. Clin Cancer Res. 2018 07 15; 24(14):3433-3446.
Score: 0.125
-
Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecol Oncol. 2017 12; 147(3):672-677.
Score: 0.120
-
High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol. 2017 07; 146(1):153-160.
Score: 0.117
-
Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth. Mol Cancer Ther. 2017 08; 16(8):1680-1692.
Score: 0.117
-
Targeting the glucocorticoid receptor in breast and prostate cancers. Sci Transl Med. 2015 Sep 16; 7(305):305ps19.
Score: 0.105
-
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014 Apr; 5(2):72-89.
Score: 0.094
-
Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. Prostate. 2012 Feb 01; 72(2):157-64.
Score: 0.078
-
Adaptive variation regulates the expression of the human SGK1 gene in response to stress. PLoS Genet. 2009 May; 5(5):e1000489.
Score: 0.068
-
Minireview: nuclear receptors and breast cancer. Mol Endocrinol. 2008 Oct; 22(10):2215-28.
Score: 0.063
-
Glucocorticoid (GC)-mediated down-regulation of urokinase plasminogen activator expression via the serum and GC regulated kinase-1/forkhead box O3a pathway. Endocrinology. 2008 May; 149(5):2637-45.
Score: 0.062
-
Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther. 2006 Aug; 5(8):933-40.
Score: 0.056
-
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer. Breast Cancer Res Treat. 2025 May; 211(1):111-119.
Score: 0.050
-
Social isolation dysregulates endocrine and behavioral stress while increasing malignant burden of spontaneous mammary tumors. Proc Natl Acad Sci U S A. 2009 Dec 29; 106(52):22393-8.
Score: 0.018